UTILIZATION AND EFFECTIVENESS OF PCSK9 INHIBITORS IN IMPROVING LIPID PROFILE IN ROUTINE CLINICAL PRACTICE

OBJECTIVES: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I) are a new class of drugs that have been shown to further reduce low-density lipoprotein cholesterol (LDL-C) by 50-70% against various background lipid-lowering therapies. We aimed to assess the use of two PCSK9-I, alirocu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-05, Vol.20 (5), p.A277
Hauptverfasser:	Yao, X, DeMartino, R, Lopez-Jimenez, F, Gersh, BJ, Sangaralingham, LR, Shah, ND, Noseworthy, PA
Format:	Artikel
Sprache:	eng
Schlagworte:	Cholesterol Clinical medicine Clinical research Clinical trials Demography Density Drug use Drugs Effectiveness Inhibitor drugs Kexin Lipid lowering drugs Lipids Low density lipoprotein Patients Propensity Proprotein convertases Statins Subtilisin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!